Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO1 | P15559 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | SOD1 | P00441 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | LTA4H | P09960 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2935967 | 0.87 | NQO1 (0.46) | NQO1TP53CYP3A4CALM1TSHR | |
| SCHEMBL11949126 | 0.85 | LMNA (0.35) | MAOBTP53LTA4H | |
| SCHEMBL2283160 | 0.83 | NQO1 (0.50) | NQO1MAOBTP53CYP3A4TSHR | |
| SCHEMBL16396585 | 0.82 | NQO1 (0.38) | NQO1MAOBTP53TSHRCHRM2 | |
| SCHEMBL288741 | 0.82 | NQO1 (0.38) | NQO1MAOBTP53CYP3A4TSHR | |
| SCHEMBL13490528 | 0.80 | CALM1 (0.51) | NQO1CALM1TSHR | |
| SCHEMBL25005892 | 0.79 | NQO1 (0.35) | NQO1MAOBTP53CYP3A4TSHR | |
| SCHEMBL1347193 | 0.79 | SLC6A4 (0.41) | MAOBKDM4E | |
| SCHEMBL1346989 | 0.79 | ALDH1A1 (0.42) | MAOBCALM1TSHRIDO1 | |
| SCHEMBL29774677 | 0.79 | ALDH1A1 (0.42) | MAOBCALM1TSHRIDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200095217-A1 | HYDROXY FORMAMIDE DERIVATIVES AND THEIR USE | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2020-03-26 | — | — | US | disclosed |
| US-10450288-B2 | Hydroxy formamide derivatives and their use | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2019-10-22 | — | — | US | disclosed |
| US-10450288-B2 | Hydroxy formamide derivatives and their use | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2019-10-22 | — | — | US | disclosed |
| CN-109970797-A | Hydroxyformamide derivatives and application thereof | 葛兰素史密斯克莱知识产权（第2 号）有限公司 | 2019-07-05 | — | — | CN | disclosed |
| CN-106103431-B | Hydroxycarboxamide derivatives and their use | 葛兰素史密斯克莱知识产权（第2 号）有限公司 | 2019-03-15 | — | — | CN | disclosed |
| US-20160340328-A1 | HYDROXY FORMAMIDE DERIVATIVES AND THEIR USE | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2016-11-24 | — | — | US | disclosed |
| US-20160340328-A1 | HYDROXY FORMAMIDE DERIVATIVES AND THEIR USE | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2016-11-24 | — | — | US | disclosed |
| US-20160340328-A1 | HYDROXY FORMAMIDE DERIVATIVES AND THEIR USE | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2016-11-24 | — | — | US | disclosed |
| EP-3092233-A1 | HYDROXY FORMAMIDE DERIVATIVES AND THEIR USE | Glaxosmithkline Intellectual Property (No. 2) Limited (GB) | 2016-11-16 | — | — | EP | disclosed |
| WO-2015104684-A1 | HYDROXY FORMAMIDE DERIVATIVES AND THEIR USE | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2015-07-16 | — | — | WO | disclosed |
| WO-2015104684-A1 | HYDROXY FORMAMIDE DERIVATIVES AND THEIR USE | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2015-07-16 | — | — | WO | disclosed |
| US-7476675-B2 | Quinolinone derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2009-01-13 | — | — | US | disclosed |
| EP-1603880-B1 | QUINOLINONE/BENZOXAZINONE DERIVATIVES AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2008-05-07 | — | — | EP | disclosed |
| EP-1603880-A1 | QUINOLINONE/BENZOXAZINONE DERIVATIVES AND USES THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2005-12-14 | — | — | EP | disclosed |
| US-20050261308-A1 | Quinolinone derivatives and uses thereof | ROCHE PALO ALTO LLC | 2005-11-24 | — | — | US | disclosed |
| US-6943169-B2 | Quinolinone derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2005-09-13 | — | — | US | disclosed |
| WO-2004080969-A1 | QUINOLINONE / BENZOXAZINONE DERIVATIVES AND USES THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2004-09-23 | — | — | WO | disclosed |
| US-20040186092-A1 | Quinolinone derivaties and uses thereof | ROCHE PALO ALTO LLC | 2004-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040186092-A1 | Quinolinone derivaties and uses thereof | NQO2, UGT1A8, UGT1A1 | NQO1 16/4885MAOB 488/4885TP53 1479/4885 |
| US-20200095217-A1 | HYDROXY FORMAMIDE DERIVATIVES AND THEIR USE | BMP1, BMPR1A, BMPR2 | NQO1 3354/4885MAOB 892/4885TP53 1650/4885 |
| US-20160340328-A1 | HYDROXY FORMAMIDE DERIVATIVES AND THEIR USE | BMP1, BMPR1A, BMPR2 | NQO1 3354/4885MAOB 892/4885TP53 1650/4885 |
| US-10450288-B2 | Hydroxy formamide derivatives and their use | BMP1, BMPR1A, BMPR2 | NQO1 3354/4885MAOB 892/4885TP53 1650/4885 |
| US-20050261308-A1 | Quinolinone derivatives and uses thereof | RECQL, NQO2, QRFPR | NQO1 19/4885MAOB 578/4885TP53 983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.